Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB87M3)

Drug Name

AZD9668 Drug Info

Synonyms

Alvelestat; 848141-11-7; AZD9668; Alvelestat (AZD9668); AZD 9668; CHEMBL3617964; AZD-9668; KB-105160; Avelestat; 6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide; 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-((5-(methylsulfonyl)pyridin-2-yl)methyl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Bronchiectasis	CA24	Phase 2	[1]
Chronic obstructive pulmonary disease	CA22	Phase 2	[2]

Cross-matching ID

PubChem CID: 46861623
CAS Number: CAS 848141-11-7
TTD Drug ID: DMB87M3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Neutrophil elastase (NE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sivelestat sodium hydrate	DMOSJD0	Acute lung injury	NB32.3	Phase 4	[4]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[5]
Sivelestat	DM6BZCV	Crohn disease	DD70	Phase 3	[6]
Tiprelestat	DM1SB94	Myocardial infarction	BA41-BA43	Phase 2	[7]
L-694,458	DMA0DSJ	Cystic fibrosis	CA25	Phase 2	[8]
BAY 85-8501	DMCPUKG	Bronchiectasis	CA24	Phase 2	[9]
DX-890	DMBFZET	Acute lung injury	NB32.3	Phase 2	[4]
POL-6014	DM9B68S	Cystic fibrosis	CA25	Phase 1	[10]
AZD-9819	DMWYHXG	Chronic obstructive pulmonary disease	CA22	Phase 1	[11]
BI 1323495	DMAUKTS	Chronic obstructive pulmonary disease	CA22	Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neutrophil elastase (NE)	TTPLTSQ	ELNE_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00769119) A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis (NEPAL). U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT00703391) A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of AstraZeneca (2009).
4	Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77.
5	Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. Bioorg Med Chem Lett. 2010 Jan 15;20(2):513-5.
6	Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203.
7	Company report (Proteo Biotech AG)
8	Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
9	Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 5-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem. 2015 Jul;10(7):1163-73.
10	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358).
11	Lipid Peroxide-Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples. Drug Metab Dispos. 2015 Oct;43(10):1441-9.
12	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight